These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35979387)

  • 1. PARP1 inhibition elicits immune responses against non-small cell lung cancer.
    Juncheng P; Lafarge A; Kroemer G; Castedo M
    Oncoimmunology; 2022; 11(1):2111915. PubMed ID: 35979387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer.
    Juncheng P; Joseph A; Lafarge A; Martins I; Obrist F; Pol J; Saavedra E; Li S; Sauvat A; Cerrato G; Lévesque S; Leduc M; Kepp O; Durand S; Aprahamian F; Nirmalathansan N; Michels J; Kroemer G; Castedo M
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35772809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
    Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer.
    Michels J; Adam J; Goubar A; Obrist F; Damotte D; Robin A; Alifano M; Vitale I; Olaussen KA; Girard P; Cremer I; Castedo M; Soria JC; Kroemer G
    Ann Oncol; 2015 Dec; 26(12):2470-7. PubMed ID: 26387143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
    Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
    PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
    Guo MZ; Marrone KA; Spira A; Scott SC
    Cancer J; 2021 Nov-Dec 01; 27(6):476-481. PubMed ID: 34904810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.
    Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA
    Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin resistance associated with PARP hyperactivation.
    Michels J; Vitale I; Galluzzi L; Adam J; Olaussen KA; Kepp O; Senovilla L; Talhaoui I; Guegan J; Enot DP; Talbot M; Robin A; Girard P; Oréar C; Lissa D; Sukkurwala AQ; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Dessen P; Saparbaev M; Soria JC; Castedo M; Kroemer G
    Cancer Res; 2013 Apr; 73(7):2271-80. PubMed ID: 23554447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.
    Mashimo M; Bu X; Aoyama K; Kato J; Ishiwata-Endo H; Stevens LA; Kasamatsu A; Wolfe LA; Toro C; Adams D; Markello T; Gahl WA; Moss J
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activity and inhibition of poly(ADP-ribose) polymerase-1 in equine peripheral blood mononuclear cells in vitro.
    Douglas HF; Southwood LL; Meyer-Ficca ML; Hart SK; Meyer RG
    J Vet Emerg Crit Care (San Antonio); 2015; 25(4):528-37. PubMed ID: 26040949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP mediated DNA damage response, genomic stability and immune responses.
    Zong C; Zhu T; He J; Huang R; Jia R; Shen J
    Int J Cancer; 2022 Jun; 150(11):1745-1759. PubMed ID: 34952967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cycleanine in cancer research: a computational study.
    Nwaefulu ON; Al-Shar'i NA; Owolabi JO; Sagineedu SR; Woei LC; Wai LK; Islam MK; Jayanthi S; Stanslas J
    J Mol Model; 2022 Oct; 28(11):340. PubMed ID: 36194315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
    Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
    Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
    Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.